title: [A trial of the use of mupirocin in the nasal carriage of Staphylococcus aureus in medical personnel].
abstract: Many hospital-acquired purulent diseases and wound infections are due to multiresistant hospital strains of Staphylococcus aureus. The role of S. aureus nasal carriage in development of wound infections due to autoinfection is confirmed. Not only inpatients but also hospital staff can be highly colonized with coagulase positive staphylococci. The S. aureus persistence in hospital personnel results in distribution of the microorganisms in the environment. Therefore, detection of S. aureus carriers without signs of the infection among the hospital personnel and eradication of the pathogen make it possible to control outbreaks of S. aureus infection in hospitals. Clinical efficacy of nasal ointment of mupirocin in the treatment of S. aureus carriers among the intensive care personnel of the N. N. Blokhin Cancer Research Center was evaluated. S. aureus nasal carriage was diagnosed in 17 (26 per cent) out of 65 persons. All the isolates were susceptible to oxacillin. 5-7 days after discontinuation of the mupirocin nasal ointment use eradication of S. aureus was stated in 100 per cent of the cases. The effect was still observed in 94 per cent of the cases in 1 month, in 76 per cent of the cases in 5-6 months and in 60 per cent of the cases in 8-9 months. It is believed that mupirocin nasal ointment (Bactroban) is convenient to use, low toxic and highly active in the treatment of persons with S. aureus nasal carriage.
authors.affiliation: Laboratory of Microbiological Diagnosis and Infection Therapy in Cancer Patients, N. N. Blokhin Russian Cancer Research Centre, Russian Academy of Medical Sciences, Moscow.
authors.forename: N V
authors.initials: NV
authors.lastname: Dmitrieva
authors.forename: F I
authors.initials: FI
authors.lastname: Solodovnik
authors.forename: I N
authors.initials: IN
authors.lastname: Petukhova
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D002353:Carrier State / Q000188:drug therapy* / Q000382:microbiology; D015169:Colony Count, Microbial; D006801:Humans; D008505:Medical Staff, Hospital; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data; D016712:Mupirocin / Q000008:administration & dosage* / Q000009:adverse effects; D009666:Nose / Q000382:microbiology; D009668:Nose Diseases / Q000188:drug therapy* / Q000382:microbiology; D009824:Ointments; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D009824:Ointments; D016712:Mupirocin